FDA Accepts BMY Myeloma Filing; LLY Eyes ATAI Deal

Bristol Myers Squibb ($BMY) secured FDA acceptance of its New Drug Application for mezigdomide in combination with carfilzomib and dexamethasone for relapsed or refractory multiple myeloma. The filing is supported by Phase 3 trial data demonstrating meaningful improvement in progression-free survival for this patient population. This regulatory milestone represents a key development for $BMY's oncology pipeline and could influence the company's future revenue mix.

Eli Lilly ($LLY) is nearing an agreement involving AtaiBeckley ($ATAI), according to Bloomberg, sending $ATAI shares up 59% in after-hours trading. A venture capital analyst noted that a rival bidder is unlikely after AtaiBeckley's months-long structured sale process, with potential takeover premium estimates reaching up to 105%. The psychedelic drug developer opportunity gained support from Johnson & Johnson's ($JNJ) stronger second-quarter sales for Spravato, its depression treatment, according to Jefferies.

UnitedHealth Group ($UNH) was set to report second-quarter results Thursday, with investors focused on confirmation that medical spending trends are under control following the company's difficult 2025. The healthcare insurer has recorded a series of gains heading into earnings season, and the report will gauge the recovery of its Medicare Advantage business. Elevance Health beat estimates for earnings and medical cost ratio, but the stock declined on concerns about high Medicaid spending. Elevance raised its 2026 adjusted earnings outlook despite lower earnings, softer membership and higher expenses, with stronger CarelonRx product revenues driving the second-quarter performance.

Intuitive Surgical ($ISRG) faces increasing global competition in robotic surgery but is responding with tiered platforms, artificial intelligence features and a broad ecosystem focused on value rather than price. The company's growth trajectory is encountering market challenges, and how management frames these dynamics reveals the real risks facing the surgical robotics leader. Johnson & Johnson ($JNJ) posted second-quarter results that beat forecasts and led the company to raise its outlook, though the stock dipped early in the trading session. The healthcare giant's performance is viewed as a positive indicator for other medtech companies including Abbott ($ABT).

Retail investors are speculating on potential Big Pharma buyout targets as Johnson & Johnson ($JNJ) pursues the number one oncology position. The company's fast-growing Inlexzo bladder-cancer franchise could make certain biotech firms either strategically attractive or direct rivals. Stocks including IBRX and SLS have attracted attention in overnight trading on buyout speculation. The Eli Lilly ($LLY) deal talks for AtaiBeckley follow a structured sale process that has lasted several months, according to a venture capital source.

The EU approved oral Wegovy across all member states, with Novo Nordisk shares rising 3% on the regulatory clearance. Retail traders noted that Eli Lilly ($LLY) is clearly behind its Danish counterpart in the oral GLP-1 space. The approval expands access to Novo Nordisk's weight-loss therapy beyond injectable formulations and represents a competitive advantage in the European market.

Bristol Myers Squibb ($BMY) possesses a strong earnings surprise history and the right combination of factors for a potential beat in its next quarterly report, according to analysis. Abbott ($ABT) is banking on emerging-market pharmaceutical growth and innovation in Nutrition, though macro pressures and currency fluctuations remain key challenges. Johnson & Johnson ($JNJ) has emerged as one of the best-performing mega-cap stocks over the past year, with questions about whether the next leg higher will break through to record territory following a recent pullback and a pipeline firing on multiple cylinders.